[Results of phase II clinical trial of vindesine in the treatment of malignant tumors].
A phase III clinical trial of vindesine-containing regimens organized by Chinese Medical Association was conducted from November 1993 to October 1994. In 799 evaluable cases, the overall response rate was 64.5% and the individual response rate was 74.1% for SCLC, 52.6% for NSCLC, 88.0% for malignant lymphomas, 62.6% for breast cancer, 57.5% for esophageal carcinoma, 59.0% for overian carcinoma and 94.0% for ALL. There were 1532 patients evaluable for toxicity. The dose-limiting toxicity was myelosuppression. Gastro-intestinal reactions, peripheral neuritis, alopecia and phlebtitis were also common. It is concluded that vindesine is similar to that reported as to response rate and toxicity.